Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Viiv Hlthcare
International Patents:672
US Patents:14
Tradenames:13
Ingredients:13
NDAs:20

Drugs and US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes 6,514,953*PED   See Pricing Y   See Pricing
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-003 Jun 9, 2016 RX Yes No 9,242,986   See Pricing Y Y   See Pricing
Viiv Hlthcare EPIVIR lamivudine SOLUTION;ORAL 020596-001 Nov 17, 1995 AA RX Yes Yes   See Pricing   See Pricing
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No 7,576,097   See Pricing Y   See Pricing
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-001 Aug 12, 2013 RX Yes Yes 8,129,385   See Pricing Y Y   See Pricing
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 AB RX Yes Yes   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RETROVIR zidovudine TABLET;ORAL 020518-001 Dec 19, 1995 4,818,538   See Pricing
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 4,828,838*PED   See Pricing
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 5,034,394*PED   See Pricing
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 5,563,142   See Pricing
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,837,208   See Pricing
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 4,833,130   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 20 mg/ml ➤ Subscribe 2012-12-27
➤ Subscribe Tablets 150 mg/300 mg ➤ Subscribe 2007-06-26
➤ Subscribe Tablets 10 mg, 25 mg and 50 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 300 mg/150 mg/300 mg ➤ Subscribe 2011-03-22
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2011-11-22
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-01-28
➤ Subscribe Tablets 700 mg ➤ Subscribe 2012-01-18
➤ Subscribe Tablets 600 mg/300 mg ➤ Subscribe 2007-09-27
➤ Subscribe Tablets 600 mg/50 mg/300 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2011-08-08

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1419152 CR 2012 00021 Denmark   See Pricing PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER HYDROCHLORID ADDITIONSSALTET AF RILPIVIRIN, OG TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128
0513917 98C0020 Belgium   See Pricing PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318
1663240 PA2015038 Lithuania   See Pricing PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128
1874117 517 Finland   See Pricing
1419152 C300529 Netherlands   See Pricing PRODUCT NAME: RILPIVIRINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT, IN HET BIJZONDER HET HYDROCHLORIDEZOUT; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
1284974 PA 2008 004, C 1284974 Lithuania   See Pricing PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Dow
Moodys
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.